Sodium-glucose cotransporter 2 inhibitors and cancer: a systematic review and meta-analysis.

Published in: Journal of endocrinological investigation (2024)

SGLT2 inhibitors did not significantly increase the overall risk of cancer or the risks of bladder and breast cancers. However, the higher risk of renal cancer associated with SGLT2 inhibitors warrants concern.

Keyphrases

papillary thyroid
squamous cell
spinal cord injury
risk assessment
urinary tract